Wireless system offers highest definition to date, according to company.
Ultrasound developer Clarius Mobile Health announced this week the launch of its new Clarius L20HD, a system designed for medical practitioners in a variety of fields.
According to company representatives, the handheld system provides ultra-high definition medical imaging for superficial applications. It can be applied in musculoskeletal services, rheumatology, podiatry, plastic and microsurgery, pediatric anesthesia, and line placement. It is designed, they said, to replace cart-based systems that are currently used to visualize shallow anatomy.
“Every medical practitioner should have access to high definition imaging to improve confidence in diagnoses and accuracy in guided procedures,” said Laurent Pelissier, Clarius chief executive officer. “We’ve miniaturized ultrasound, without compromising image quality."
The system, which has 510(k) clearance from the U.S. Food & Drug Administration, as well as the CE Mark from the European Union, offers a frequency range of 8-to-20 MHz, enabling images down to 4 cm, and it features eight octal beams and 192 elements that provide for faster frame rates.
In addition, company officials said, it is compatible with both iOS and Android systems and can deliver images that are equivalent in quality to those captured by cart-based system, according to company details. Artificial intelligence can also adjust imaging parameters based on scanning application in real time.
The system retails for $6,900 in the United States compared to the $35,000 price tag for a cart-based system.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.